View in EDS

Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.

Saved in:
Bibliographic Details
Title: Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
Authors: Douma, Li-Anne H1 (AUTHOR), van der Noort, Vincent2 (AUTHOR), Lalezari, Ferry3 (AUTHOR), de Vries, Jeltje F2 (AUTHOR), Monkhorst, Kim4 (AUTHOR), Smesseim, Illaa1 (AUTHOR), Baas, Paul1 (AUTHOR), Schilder, Bodien1 (AUTHOR), Vermeulen, Marrit2 (AUTHOR), Burgers, Jacobus A1 (AUTHOR) s.burgers@nki.nl, de Gooijer, Cornedine J1 (AUTHOR)
Source: Lancet Oncology. Dec2025, Vol. 26 Issue 12, p1676-1684. 9p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first